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Abstract

Investigation of the interactions between the DREAM complex and HPV16
By Kevin M. Ko
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Physiology and Biophysics at Virginia Commonwealth University
Virginia Commonwealth University, 2019
Directed: Dr. Iain M. Morgan, PhD
Edmund G. Brodie Professor
Director, VCU Philips Institute for Oral Health Research
Chair, Oral and Craniofacial Molecular Biology
VCU School of Dentistry
According to the American Cancer Society, it has been estimated that in 2019 alone,
there will be approximately 53,000 new cases of oropharyngeal cancers. Oropharyngeal cancers
are the largest subset of head and neck squamous cell carcinomas (HNSCCs), which are the sixth
most common cancer across worldwide populations. They, along with other HNSCCs, fall under
a category of cancers known as Human papillomavirus (HPV)-associated cancers, and it has
been found that upwards of 70% of these cancers can be attributed to high-risk HPV infections.
Specifically, the high-risk HPV gene, E7, plays a key role in relieving cell cycle
repression by disrupting the DREAM complex via competitive binding with p130, driving the
cell cycle and cell proliferation. In order to combat this interaction, a LIN52-S20C mutation was
developed, in hopes of reducing E7 binding of p130 and stabilizing the DREAM complex. We
utilized human cervical cell lines, immortalized keratinocytes, and mouse fibroblasts, all of
which contained the HPV16 genome, as models to observe the effects of the LIN52-S20C
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mutation on HPV-mediated hijacking of the cell cycle. Not only were we able to replicate the
increased proliferation and upregulated DREAM gene expression in infected cells, but we were
also able to observe some reversal of these effects in many of our cell models through the
expression of the LIN52-S20C variant. The findings of these studies have been promising and
provide a basis for future works, and we hope that the effects of the LIN52-S20C mutation can
be translated into studies in in vivo models.

v

1. Introduction
1.1 Head and Neck Cell Carcinoma Statistics
In 2019 alone, it has been estimated that there will be approximately 53,000 new cases of
oropharyngeal cancers.1,2 Oropharyngeal cancers are the largest subset of head and neck
squamous cell carcinoma (HNSCC), which is the sixth most common cancer across worldwide
populations.3 Individuals that have been diagnosed with oropharyngeal cancers require constant
monitoring due to the oral cavity’s connections with the aerodigestive tract.4 Even patients who
have appeared to eliminate traces of oral and oropharyngeal cancers are at risk of developing
neoplasms in secondary locations within the aerodigestive tract, such as the esophagus or the
lungs.2 Oropharyngeal cancers, along with other HNSCCs, fall under a subset of cancers known
as Human papillomavirus (HPV)-associated cancers, which have been defined as cancers which
occur in areas of the body where HPV can often be found, with cervical cancer being the most
prevalent.5,6 Of those cancers located within the head and neck, it has been found that upwards of
70% of them can be attributed to some sort of HPV infection.5,7 In fact, HPV has been linked to
5% of all cancers worldwide.8 While the overall incidence of HPV-unrelated HNSCCs has
decreased due to several factors, including the decrease in tobacco use, the number of HPVassociated HNSCCs has continued to increase dramatically.9-11
1.2 Human Papillomavirus
Human papillomavirus is the most commonly sexually transmitted infection in the United
States, with a prevalence of 80 million cases in the US alone.4,12 By the age of 50, approximately
4 out of every 5 women will have come into contact with and been infected by HPV, and in the
United States, approximately 1 in 4 people are currently infected with the virus.12,13 However,
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most individuals will not display any symptoms, and within two years, the immune system can
rid the body of the infection.12 There are five genera of human papillomavirus types, which have
been determined by their DNA sequences as well as their differences in their life cycle
progressions. The genera that is most studied and most commonly associated with cancers is the
Alpha type.14 Alpha papillomaviruses have two modes of infection: cutaneous and mucosal.14
The mucosal form can then be further classified into two categories: low-risk and high-risk. The
former is associated with wart formation, while the latter is responsible for cancer and pre-cancer
development.13,14 For the sake of simplicity, the two forms will simply be referred to as low-risk
and high-risk HPVs. There are 13 high-risk HPV types that have been classified as being
carcinogenic.13 If the immune system is unable to rid the body of the high-risk HPV infection, it
can linger and eventually lead to the development of transformed cells and cancer.13 Of the HPV
types that are considered high-risk, HPV16 has been found to be most strongly associated with
oropharyngeal cancers, with a 95% prevalence.15
1.3 Vaccination and Therapy
Currently, prophylactic treatment via vaccination is the sole, effective means of
preventing HPV infections.8 In the United States, there are two primary HPV vaccinations that
are available that utilize a recombinant form of the viral capsid protein.8 The first, Gardasil 9, is a
quadrivalent vaccine that was developed to prevent infections from nine different HPV types: -6,
-11, -16, -18, -31, -33, -45, -52, and -58. The second vaccine, Cervarix, is a bivalent vaccine that
can be administered to prevent HPV types -16 and -18 infections.9 While both of these vaccines
have shown extremely high efficacy, at approximately 97%, for the prevention of cervical precancers, there is no data regarding their use against HPV-related head and neck cancers.9,10
However, another issue that arises with the reliance on these vaccinations is that the
2

responsibility falls on the general population to follow a strict multi-dosage regimen. A survey
taken by the Center for Disease Control and Prevention (CDC) showed that approximately only
27% of females aged 13-17 had successfully completed the series of HPV vaccinations.9 This
problem is only exacerbated by the fact that populations that are at risk for developing HPVrelated cervical cancer overlap with populations that are at risk for failing their vaccinations or
have compromised access to the vaccines.9 Finally, it is important to keep in mind that these
vaccines are prophylactic, meaning they are only effective as a preventative measure and do not
provide much protection once infection has taken place.
Currently, the most common treatments for HNSCC are surgery or radiotherapy, with
more advanced cases requiring a combination of both. Recently, there has been an increase in
alternative treatments, such as cisplatin-based chemotherapy and targeted drugs.16 However,
despite these advancements, the five-year survival rate for patients diagnosed with HNSCC
remains at around 40-50%.16 Surprisingly, it has been found that HPV-positive HNSCC patients
have a more favorable rate of survival when compared to HNSCC patients that were HPVnegative.15,16 However, the reason for this positive prognosis has yet to be determined, and
studies have even shown a decreased sensitivity to drugs in HPV-positive tumor cells compared
to HPV-negative tumor cells.16
1.4 High-Risk HPV Genome
HPVs are small, circular, double-stranded DNA viruses. They are approximately eight
kilobases in length and encode eight main genes, consisting of non-structural early genes (E1,
E2, E4, E5, E6, and E7) and structural late genes (L1 and L2), although there has been evidence
for other proteins and isoforms that may have important viral functions.17,18 The genomes also
contain a regulatory region known as the long control region, or the LCR, which contains the
3

DNA replication origin and functions as a replication and transcription regulator.18 The E1 and
E2 proteins work together to initiate replication of the viral DNA. E1 expression can be seen
throughout the HPV life cycle, and it has ATP-dependent helicase activity that recognizes ATrich sequences in the origin of replication.8 However, E1 cannot bind to the origin alone and
requires the assistance of E2. The E2 protein is a DNA-binding protein that plays a role in both
replication and transcription. It recognizes specific sequences in the LCR and interacts with E1
to recruit it to the origin.8 Although E4 falls under the early genes, it is actually expressed
relatively late in the HPV life cycle, and its full functions are still unclear.17 However, we do
know that it is involved in disrupting the cytokeratin filaments to help facilitate the release of the
virus. It is also most commonly expressed as an E1^E4 fusion protein8, which is actually the
most highly produced protein in the virus’s life cycle and is involved in S phase maintenance and
HPV16 genome amplification during differentiation.19 E6 and E7 are the two oncoproteins that
are primarily responsible for driving the transformation and cell proliferation of HPV-infected
cells.20,21 In high-risk HPV, the main role of the E6 protein is to target the p53 tumor suppressor
for degradation via ubiquitination by forming a complex with the ubiquitin ligase E6-associated
protein (E6AP).21,22 With the degradation of p53, E6 is able to inhibit apoptosis. It also has other
functions, including binding PDZ proteins and telomerase activity, resulting in decreased
epithelial integrity and promoting immortalization of cells, respectively.8 E7 is the other major
protein that is responsible for immortalization and transformation.21 It drives the cell cycle and
genomic stability by targeting retinoblastoma (Rb)-family members8,20,21 for degradation via
ubiquitination by associating with the Cullin 2 ubiquitin ligase.23 E5 is also considered an
oncogene;8 however, its effects are minor compared to those of E6 and E7, and loss of E5 cells
infected with high-risk HPV has shown little effects on their transformative properties. It is a
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transmembrane protein that has been shown to potentiate E6’s and E7’s transformative
properties. By itself, it has been shown to drive proliferation and inhibit apoptosis through its
binding to the epidermal growth factor (EGF).8 Finally, L1 and L2 are the major and minor
capsid proteins, respectively, and they are vital for virus assembly.8,20

Figure 1. HPV16 Full genome. The image shows the full circular genome of high-risk HPV16 with its 8
different genes: E1, E2, E4, E5, E6, E7, L1, and L2. It also displays the LCR, which binds to transcription
factors, as well as E1 and E2. P97 is the early promotor, and P670 is the late promoter. AE is the location
for early polyadenylation and AL is the location for late polyadenylation. Adapted from Kajitani et. al,
2012.20

Apart from the individual genes that make up the HPV genome, another important
characteristic is its genomic state. Through the observation of HPV16-infected HNSCC, it was
discovered that there are three main states of the HPV genome in tumors: an episomal state, an
integrated state, and an episomal hybrid state with human DNA. The episomal state of the HPV
5

genome exists in a circular DNA structure, and it has autonomous replicative properties. In the
integrated state, the HPV genome is inserted and maintained within the human genome, and the
incidence of this state can be identified by the loss of the E2 expression, along with E4 and E5.
While episomal and integrated states of HPV genomes have been previously identified in HPVrelated cervical cell lines, the discovery of viral-human episomal hybrids in head and neck
cancer has been much more recent. In fact, they were originally misidentified as being a
combination of episomal and integrated viral genomes existing within the same tumor.24 As
stated previously, patients with HPV-related HNSCC have a higher rate of survival than
individuals with HPV-unrelated HNSCC. However, it has been found that the state of the viral
infection plays a major role. While the survival rates of patients with episomal HPV matched the
higher rates for those with HPV HNSCC in general, patients with integrated HPV had survival
rates that more closely resembled those of patients with non-HPV HNSCC. Luckily, the
integrated state of HPV is much less common than the episomal state and is found in
approximately 17% of HPV samples. There is also evidence that suggests that there has been a
shift in the genomic state from the integrated state to the episomal state over time in cervical
cancer; however, it has yet to be confirmed in HNSCC.25
1.5 HPV Life Cycle
The HPV viral lifecycle cannot be fully understood without first understanding the
differentiation process of the human squamous epithelium. In normal, healthy stratified
epithelium, the basal cell, which is located adjacent to the basal membrane, has the sole potential
to proliferate. When the basal cell undergoes cell division, it results in a replacement basal cell
along with a daughter cell that is no longer attached to the basal membrane. These daughter cells
are then able to differentiate into the various layers of the epithelium, until they are terminally
6

differentiated to form cornified keratinocytes and are peeled away from the epithelium.20,21 This
process of differentiation is vital for the viral lifecycle of HPV, which can be broadly divided
into four phases.
The first phase of the viral lifecycle is the infection of the basal layer of the epithelium.
Since the basal cells are the only epithelial cells that are capable of undergoing proliferation, the
virus must be able to infect these cells. Given that the basal cells are in the innermost layer of the
epithelium, successful infection requires microlesions that allow the virions access to the
cells.14,20 It has been suggested that the virions initially recognize the heparan sulfate
proteoglycans (HSPGs) on the basal membrane.8,20 This binding results in a conformational
change that allows them to have greater binding affinity for receptors on the keratinocytes, where
the virions are endocytosed into the cells.7 The virions are then uncoated,20 and the genome is
trafficked to the nucleus following nuclear envelope breakdown.26
Following successful infection, there is a brief period of genome amplification prior to
the maintenance phase26, where the viral genome is kept at a relatively low copy number,
ranging from 50 to 100 copies.8,20 E1 and E2 are some of the earliest proteins to be expressed
and are even thought to be required for the initial amplification. However, they might not be as
vital once the copy numbers have been established.8 The basal cells remain infected throughout
this period through the replication of the viral genome with each cell cycle. The viral genome
can remain latent in this maintenance phase for an extended period of time, even lasting up to
decades.8
The amplification phase of the viral life cycle occurs when the viral genome exits the
basal layer and enters the differentiating cells.27 While E1 and E2 play an important role in the
viral DNA replication, they are not enough. As a result, HPVs require polymerases and other
7

enzymes from the host, which are recruited by E1 and E2.8 However, once cells have left the
basal layer and begun differentiating, they are unable to undergo proliferation via the cell cycle.
To overcome this obstacle, HPVs utilize E6 and E7 to allow the cells to re-enter S-phase and the
cell cycle. As stated earlier, these proteins target p53 and Rb-family proteins, which are both
necessary for growth arrest in the differentiated cells. By inactivating these targets, HPVs can
modify the cells to continue viral genome amplification and cell proliferation. Loss of E7 has
resulted in a drastic disruption of this phase and the cell’s ability to synthesize viral DNA, even
in the presence of the viral E6 protein.28 During this period of amplification, the number of
copies can reach up to thousands per cell.27
Finally, before the virus can exit its lifecycle, it must package its genome. In the nuclei of
terminally differentiated epithelial cells, the L1 and L2 genes are expressed. These two proteins
are necessary for the virion assembly and packaging of the viral genome.8,20,27 Maturation of the
virions occurs in the most superficial layers of the terminally differentiated cells, and during the
maturation, the capsid is stabilized resulting in increased stability and resistance.8 HPVs do not
require lytic behavior to release the virions but instead, are released during the natural shedding
of the keratinocytes.27
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Figure 2. The HPV life cycle relies on the cell cycle. In normal, healthy epithelium, the basal layer
contains the proliferating cells. When the cell replicates and exits the basal layer, it undergoes the
differentiate process through the various layers of the epithelium. When the HPV virions enter the
epithelium, they infect the basal layer. The diagram shows the separation in the expression of the early
genes versus the late genes. Once L1 and L2 are expressed in the uppermost layers, the virions are
assembled and shed. Adapted from Kajitani et. al, 2012.20

1.6 DREAM Complex
It has been well established that, in order for the cells to undergo differentiation, it is
necessary for cell cycle exit, or quiescence. This process of quiescence has been linked to a
specific complex of proteins known as the DREAM complex, which is short for the dimerization
partner, retinoblastoma-like, E2F, and MuvB complex.29,30 The MuvB core consists of LIN9,
LIN37, LIN52, LIN54, and RBBP4.31 During the S-phase of the cell cycle, when the cell is
proliferating, the core associates with Bmyb to form the Bmyb-MuvB (MMB) complex. It can
then bind to promoters of G2/M genes and act as an activator.35 However, in order to prevent
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uncontrolled proliferation, it is necessary for the MuvB core to bind to p130 or p107 to maintain
the DREAM complex. p130 and p107 are two proteins that belong to a larger family known as
pocket proteins; of these pocket proteins, the most well-known one is the retinoblastoma tumor
suppressor (Rb).30,32 In the mammalian cells, MuvB primarily associates with p130 to form
DREAM, and they bind to the repressor E2F 4/5 transcription factors to promote quiescence
during G0 and G1.33
Of all the proteins within the DREAM complex, we chose to focus on the LIN52 subunit
of the MuvB core because of its vital role in DREAM assembly. LIN52 is involved in the
complex assembly through its interactions with p130. p130 and other members of the pocket
protein family contain two interfaces with which they can interact with other proteins. The first
interface is the E2F transactivation domain (E2FTD)-binding site and the second is the LxCxE
cleft.29 The LxCxE cleft will bind to any protein, both viral and endogenous, that contains the
specific LxCxEφ sequence, where x can be any amino acid and φ is any hydrophobic amino acid.
While LIN52 does not contain the exact sequence, it does contain a suboptimal LxSxExL motif
at residues 18 to 24.29 Although this motif has a decreased affinity for binding to pocket proteins,
LIN52 has developed a mechanism that allows for increased specificity and the ability to
regulate its binding to the pocket proteins. When co-immunoprecipitated with p130 or p107,
LIN52 was found to be phosphorylated at serine 28 (S28) residue. This phosphorylation of S28
greatly increased the affinity for LIN52 binding to both p130 and p107 because of the presence
of a phosphate-binding pocket in both of the pocket proteins. This phosphorylation event is
accomplished by the dual specificity tyrosine-phosphorylation-regulated kinase 1A
(DYRK1A).29,31,33 Mutations in DRYK1A activity, the LxSxExL motif, and serine 28 have all
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shown to disrupt the assembly of the DREAM complex, ultimately limiting the cell’s ability to
exit the cell cycle and enter quiescence.31,33
Phosphorylation is also used to promote disassembly of the DREAM complex. While the
phosphorylation of S28 in LIN52 is required for DREAM assembly, dephosphorylation by itself
is not sufficient for promoting disassembly. In fact, LIN52 S28 can be found in both its
phosphorylated and unphosphorylated forms when MuvB is bound to Bmyb.29 Instead,
disruption of the DREAM complex relies on cyclin-dependent kinases (CDKs). Specifically,
CDKs phosphorylate p130 and p107 at various sites, including threonine 401 (T401), and affect
their ability to bind to LIN52 by provoking a structural change that results in an obstruction of
the LxCxE cleft.29,34,36

Figure 3. The MuvB core can form either the DREAM or MMB complexes. The MuvB core, which
consists of LIN9, LIN37, LIN52, LIN54, and RBBP48, can form a complex with p130 during G0-G1 to
form the DREAM complex and repress transcription, or it can form a complex with BMYB during S-G2
to activate gene transcription. Adapted from Dr. Claire James, VCU.
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1.7 Interaction between E7 and DREAM
Since p130 plays a pivotal role in the assembly of the DREAM complex and ultimately
quiescence, it is no surprise that HPV targets it for degradation. The role of the HPV gene E7
was briefly mentioned, along with its transformative properties and ability to drive cell cycle
progression. In fact, it has been found that the gene is necessary for the amplification phase in
differentiated cells during the viral life cycle.28 E7 is required to establish an environment that
could allow for viral DNA amplification in cells that are normally unable to do so.37,38
HPV16 E7 is able to target p130 and the other pocket proteins by direct binding via their
LxCxE cleft, much like LIN52. However, unlike LIN52, which contains a suboptimal LxSxExL
motif, the E7 protein contains the exact canonical LxCxE, resulting in a greater binding affinity
for p130.39,40 This stronger binding affinity allows E7 to outcompete LIN52 for binding of p130,
ultimately disrupting the DREAM complex.40,41 When the DREAM complex is disassembled,
there is a release of the repressor E2F4 transcription factors,42,43 allowing for the expression of
multiple cell cycle genes, including several activating E2F transcription factors and DREAM
target genes.43 Normally, Rb can serve as a checkpoint during G1/S by regulating and repressing
these activating E2Fs. However, high-risk HPV E7 is also able to target Rb.41 As a result, E7’s
ability to disrupt the DREAM complex and relieve repression of activating E2Fs is required for
the formation of pre-cancerous lesions and eventually the transformation of the cells, even in the
presence of other oncogenes, such as E6.44 It is important to note that there are also other critical
non-RB E7 targets that are not discussed here.45
Not only is HPV16 E7 able to bind to p130 to disrupt the DREAM complex but it is also
able to target p130 for proteasome-mediated degradation. HPV16 E7 specifically recruits the
cullin 2 ubiquitin ligase, which is used to ubiquitinate the Rb and pocket protein substrates.23
12

Figure 4. HPV16 E7 interaction with p130. The HPV oncogene E7 binds to the pocket protein, p130, via its
LxCxE cleft and can target it for proteasomal degradation via ubiquitination. This process disrupts the DREAM
complex and lifts repression of transcription factors. Adapted from Rashid et. al, 2015.36

1.8 LIN52-S20C Mutation
In order to combat the effects that HPV16 E7 has on the binding between p130 and
LIN52, the Litovchick lab developed a LIN52 mutant that substitutes the Serine at residue 20 for
a Cysteine (S20C). With this mutation, LIN52’s initial sequence, LxSxExL has become
LxCxExL, which is more in line with the LxCxE cleft of p130 and the other pocket proteins. The
hope is that with the increased binding affinity that the mutated sequence provides, LIN52 will
no longer be outcompeted for p130 binding by HPV16 E7. Initial studies have been promising
and have shown that the LIN52-S20C mutation may be sufficient in competing for p130 binding
against other viral proteins that contain the same LxCxEφ motif. A LIN52-p130 coprecipitation
assay was performed with both the wild-type and S20C mutant variants of LIN52 in the presence
of E1A or large T-antigen viral proteins, which both contain LxCxEφ. The results showed that
LIN52-S20C coprecipitated with a much larger amount of p130 compared to the wild-type
13

counterpart.29 This suggests that the mutation is much more successful in competing against viral
proteins for binding of p130.
1.9 Preliminary Data
Before I started my project here at the Philips Institute for Oral Health Research, my
colleagues were able to gather important, relevant data that laid a solid foundation for my work.
Tara Nulton, a former member of the Philips Institute, was able to gather RNA sequencing data
that shows that many DREAM and MMB regulated genes are significantly upregulated in cells
that have been infected with the full HPV genome. Specifically, normal oral keratinocytes
(N/TERT-1s) were infected with HPV16, and the sequencing showed that out of 710 DREAM
genes, 182 of them were significantly upregulated, and out of 666 MMB genes, 84 of them were
significantly upregulated.
Dr. Claire James also produced growth curves for HeLa and SiHa cells, which are
cervical cancer cell lines that are positive for high-risk HPV. For both cell lines, four different
variants were used: parental, green fluorescent protein (GFP) infected, LIN52 infected, and
LIN52-S20C infected. The growth curve data showed that when the cancer cells were infected
with the LIN52-S20C mutant, their cell proliferation was noticeably decreased when compared
to the other HeLa and SiHa variants.
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Figure 5. HeLa and SiHa Growth Curves. In both the HeLa and SiHa cell lines (A, B), the variants
containing the LIN52-S20C mutation show a decrease in cell proliferation when compared to the parental,
GFP, and LIN52 variants. Adapted from Dr. Claire James, VCU.
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1.10 Rationale for Study
Based on the initial findings from studies performed with the LIN52-S20C, we believed
that there was sufficient reason to suggest that the mutation could be successful in combating the
effects of high-risk HPV16 in head and neck squamous cell carcinoma. More specifically, we
hope that the LIN52-S20C mutation can compete against the interaction between high-risk HPV
E7 and p130 and ultimately stabilize the DREAM complex. Through the stabilization of the
DREAM complex, we can reestablish repression of the cell cycle and prevent the rampant cell
proliferation that is necessary for HNSCC.

2. Methods and Materials
2.1 Cell Culture
Media
For cell cultures, various media were used in combination with different supplements,
depending on the cell line.
• Dulbecco’s Modified Eagle Medium (DMEM) with 4.5 g/L D-Glucose, L-Glutamine, and 110
mg/L sodium pyruvate (Fisher Scientific; Hampton, NH)
• Keratinocyte-SFM (K-SFM) with L-Glutamine, epidermal growth factor (EGF), and bovine
pituitary extract (BPE) (Fisher Scientific; Hampton, NH)
Supplements
Along with the different media that were used, some cells required supplements that
contained various growth factors and nutrients.
16

• Fetal bovine serum (FBS)
• Newborn calf serum (NCS)
HeLa and SiHa Cells
HeLa and SiHa cell lines were both established directly from patients diagnosed with
HPV-related cervical cancer cells. Therefore, they have been immortalized and transformed by
the virus. SiHa cells are derived from high-risk HPV16 and HeLa are derived from high-risk
HPV18. Although these cell lines are cervical, they provide a strong foundation and share many
similarities to HPV-related head and neck cancer cells. The cells were provided to us by Dr.
Larisa Litovchick’s lab, VCU. The cells were cultured in DMEM + FBS media at 37°C in a 5%
CO2/95% air atmosphere.
N/TERT-1 Keratinocytes
These keratinocytes were immortalized, which allows us to make comparisons between
the parental lines and the modified, infected lines. Although they have not been immortalized by
HPV, they can still be infected to express the full HPV genome. Htk16s are human tonsil
keratinocytes that have been immortalized by the HPV16 genome and share many morphological
similarities with the N/TERT-1 keratinocytes. N/TERT-1s were cultured in K-SFM media at
37°C in a 5% CO2/95% air atmosphere. N/TERT-1s + HPV16 were grown in K-SFM with 150
µg/mL of G418.
Mouse Embryonic Fibroblasts (MEFs)
These MEFs have been specifically bred by the Litovchick lab to express either the wildtype LIN52 protein or the mutant LIN52-S20C variant. Unlike the other cell lines, MEFs are not
immortalized and have a limited number of passages. However, they can be virally infected to
17

become immortalized. The cells were cultured in DMEM + NCS media at 37°C in a 5%
CO2/95% air atmosphere.
293TT Cells
293TTs are derived from human embryonic kidney 293 (HEK293) cell lines. They were
transfected with the SV40 genome and express small T-antigen. They also contain a SV40 large
T-antigen cDNA expression cassette that promotes large T-antigen expression. These cells are
used for their ability for transfections and are able to replicate any plasmid that contains the
SV40 origin of replication. These cells were obtained from the Litovchick Lab, VCU. The cells
were cultured in DMEM + FBS media at 37°C in a 5% CO2/95% air atmosphere.
NIH 3T3 Cells
NIH 3T3 cells are another line of mouse embryonic fibroblasts that were originally
derived from an isolated cell line. It is widely considered one of the most used cell lines and has
become the standard for fibroblast lines. They were obtained from the National Institutes of
Health (NIH). The cells were cultured in DMEM + FBS media at 37°C in a 5% CO2/95% air
atmosphere.
3T3-J2 Cells
These J2 cells are a subclone of the original 3T3 fibroblasts. They are primarily used as
feeder cells for human and mouse epithelial keratinocytes. They were obtained from the NIH.
The cells were cultured in DMEM + FBS media at 37°C in a 5% CO2/95% air atmosphere.
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Table 1. Summary of Cell Lines and Media
Cell Line

Media

HeLa

DMEM + FBS

SiHa

DMEM + FBS

N/TERT-1

K-SFM

HTK16

K-SFM

MEF

DMEM + NCS

293TT

DMEM + FBS

NIH 3T3

DMEM + FBS

3T3-J2

DMEM + FBS

2.2 Growth Curves
The different cell lines were taken from frozen stock held in nitrogen tanks. They were
then defrosted and slowly pipetted into 4 mL of their corresponding media in 15 mL tubes. The
cells were then spun down in a centrifuge for 5 minutes at 500 RCF, and the media was aspirated
off. The cells were then resuspended in the media and plated onto two 10 cm per cell line. They
were then left to grow in an incubator at 27°C.
Once the cells reached approximately 70-80% confluency, they were removed from the
incubator and the media was aspirated off. They were then washed with 5 mL of Phosphatebuffered saline (PBS) and trypsinized with 2 mL of Trypsin-EDTA (Fisher Scientific; Hampton,
NH). Once the cells were budded off from the dishes, they were neutralized with 4 mL of their
corresponding media and spun down in the centrifuge for 5 minutes at 500 RCF. Once the cells
were fully spun and pelleted, the media was removed, and fresh media was added. Depending on
the size of the pellet, anywhere from 4 to 8 mL of media was added to resuspend the pellet.
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After resuspending the cells in fresh media, 10 µL were taken up and added to a cellcounting chamber. The number of cells were counted in 16 squares of the chamber to determine
the cell counts for each cell line. The amount was recorded, and calculations were performed to
plate two new dishes of each cell line at 3 x 105 to 5 x 105 cells per dish. The counting and replating steps were repeated until enough counts were obtained to generate a growth curve.
2.3 Cell Transfection
In order to make retrovirus, a lipofectamine transfection assay was performed. First,
293TT cells were seeded onto 10 cm3 dishes and left to incubate until they were approximately
70% confluent. The number of dishes corresponded with the number of infections that were
going to be performed.
We then calculated the amount of DNA that would be required so that 5 µg of DNA was
added to each dish of cells. Of the 5 µg of DNA, 1 µg consisted of gagpol, 1µg consisted of vsv,
and the remaining 3 µg consisted of the desired plasmid that was being transfected. In a 24-well
plate, 400 µL of optimum media was added to twice as many wells as plates that were being
transfected; the media was arranged into two rows. In the top row of media, 20 µL of
lipofectamine was added; in the bottom row, the 5 µg of DNA that was previously calculated
was added. The contents of the top row were then added to the bottom row, and they were mixed
by pipetting and left at room temperature for 20 minutes.
The 293TTs that were seeded and at 70% confluency were removed from the incubator
and the media was aspirated off. 8 mL of serum free DMEM media was added to the dishes as
well as 400 µL of the transfection mix, and they were left to incubate for 4 to 6 hours. After the
incubation period, the media was aspirated off and 10 mL of fresh DMEM media was added.
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Depending on the target cells that were being infected, either FBS or NCS serum media was
used.
The following day, the viral supernatant was removed from the transfected 293TT dishes
and transferred to a syringe with a 0.45 µm filter. The supernatant was then added directly onto
the target cells along with 4 µg/mL of polybrene. Fresh media was added onto the 293TT cells,
and the infection using the same process was repeated the next day. It was critical that during the
handling of the viral supernatant, every piece of equipment that came into contact with the
retrovirus was thoroughly disinfected using bleach.
2.4 RNA Isolation
RNA was isolated from the cells using the ISOLATE II RNA Mini Kit and the protocol
provided by Bioline. Once the RNA was purified, the concentration was determined using a
nanodrop spectrophotometer.
ISOLATE II RNA Mini Kit Contents:
• ISOLATE II Filters
• ISOLATE II RNA Mini Columns & Collection Tubes
• Lysis Buffer RLY
• Wash Buffer RW1
• Wash Buffer RW2
• Membrane Desalting Buffer MEM
• Reaction Buffer for DNase I RDN
• DNase, RNase-free (lyophilized)
• RNase-free Water
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2.5 cDNA Synthesis
Using the RNA concentration that was determined using the nanodrop, calculations were
made to collect 2 µg of RNA per sample with a total volume of 20 µL. The High Capacity cDNA
Reverse Transcription Kit from Thermo Fischer Scientific was used and programmed for 25°C
for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes, and 4°C indefinitely. Once the cDNA
was synthesized, each sample was diluted 1:5 by adding 80 µL of deionized water.
The High Capacity cDNA Reverse Transcription Kit Contents:
• 10X RT Buffer (1 mL)
• 10X RT Random Primers (1 mL)
• 25X dNTP Mix (100 mM, 0.2 mL)
• MultiScribe® Reverse Transcriptase (0.2 mL at 50 U/µL)
• RNase Inhibitor (1 × 0.2 mL at 20 U/µL
2.6 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Depending on how many primers were being tested, the cDNA samples were diluted
once more in deionized water, using a 1:10 dilution. The total volume of each dilution was
calculated so that each of the two repeats for every primer would contain 5 µL of the diluted
cDNA sample. The samples were then pipetted into a 96-well plate, with 5 µL in each well.
A master mix was created for each primer, taking into account two repeats for every
sample that was being tested. The master mix consisted of 1 µL of primer, 10 µL of PerfeCTa
SYBR Green FastMix (Quantabio; Beverly, MA), and 4 µL of deionized water for each sample.
For each well, 15 µL of the master mix was added for every 5 µL of sample cDNA. GAPDH
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primer was used for every run of qRT-PCR as a control. The 96-well plates were then sealed and
spun down.
The plates were then placed in a 7500 Fast Real-Time PCR System (Applied Biosystems;
Carlsbad, CA) and programmed to run a quantitation for comparative CT (ΔΔCT) for a standard
2 hour run. The standard run consists of 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of
95°C for 15 seconds, and 60°C for 1 minute. The data collection and analysis were conducted
using the 7500 Fast Real-Time PCR System.
Table 2. List of Mouse Primers
Mouse Primers
GAPDH
Forward
Reverse
Birc5
Forward
Reverse
BMYB
Forward
Reverse
Bub1
Forward
Reverse
Cdc6
Forward
Reverse
Cdc25c
Forward
Reverse
Cyclin A2
Forward
Reverse
Cyclin B1
Forward
Reverse
FoxM1
Forward
Reverse
Kif23
Forward
Reverse
Lin9
Forward
Reverse
Lin37
Forward
Reverse
Mcm5
Forward
Reverse
p107
Forward
Reverse

5`-TGTGTCCGTCGTGGATCTGA-3`
5`-TTGCTGTTGAAGTCGCAGGAG-3`
5`- CACCTTCAAGAACTGGCCCT-3
5`-ATCGGGTTGTCATCGGGTTC-3`
5`-AACAGTGGACGCTGATAGCCA-3`
5`-TTCACAGCATTGTCCGTCCTC-3`
5`- TGTTTGAAGCCCATATGCAA-3`
5`-CGGTCACTGTTGTACTCAGCA-3
5`-AATCCATCCTGCTGAATTGC-3`
5`-ATACATCCTGCCCTTTGCTG-3`
5`-ACGACTCGGCAAACCTAAGC-3`
5`-TAGTAAGCGGAGAGGCAGAC-3`
5`-CGGAGCAAGAAAACCACTGAC-3`
5`-ACCAGCCAGTCCACAAGGATG-3`
5`-AAGGCCAAGGTCAGTATGGC-3
5`-CTCAGGCTCAGCAAGTTCCA-3`
5`-GCAGCGTTAAGCAGGAACTG-3
5`-AGAGTAGGGTGGCCTCTCAG-3`
5`- AAGCGGGTATTTGGCACTCA-3`
5`- CAAACAACGAGGAAGCAGGC-3
5`-TGTTTGGAAAGGCAGGAATGC-3`
5`-GTGGGATCATTGCCACTCTC-3`
5`-CACACCACTGTACCCCATCT-3`
5`-GGAGGCAGCTTGTACACATCA-3`
5`- GACATCCAGGTCATGCTCAA-3`
5`-AGGGATCTTCACCAGGTGTG-3`
5`-GGGAAAGGGCGTCATGGAAG-3`
5`-AGCCTTTCTATCCGCTCACGA-3
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150 bp
162 bp
208 bp
217 bp
210 bp
102 bp
249 bp
252 bp
128 bp
183 bp
143 bp
159 bp
90 bp
150 bp

Table 3. List of Human Primers
Human Primers
GAPDH
Forward
Reverse
Aurora
Forward
Reverse
BIRC5
Forward
Reverse
BMYB
Forward
Reverse
BRCA1
Forward
Reverse
BRIP1
Forward
Reverse
DYRK1A
Forward
Reverse
FANCD2
Forward
Reverse
IL24
Forward
Reverse
KIF15
Forward
Reverse
KIF23
Forward
Reverse
LIN9
Forward
Reverse
LIN52
Forward
Reverse
P107
Forward
Reverse
PLK1
Forward
Reverse
POLE2
Forward
Reverse
QRFPR
Forward
Reverse
RTKN2
Forward
Reverse
SLC43A3
Forward
Reverse
TNC
Forward
Reverse

5’-CAATGACCCCTTCATTGACC-3’
5’-TTGATTTTGGAGGGATCTCG-3’
5’-GGAATATGCACCACTTGGAACA-3’
5’-TAAGACAGGGCATTTGCCAAT-3’
5’-AGGACCACCGCATCTCTACAT-3’
5’-AAGTCTGGCTCGTTCTCAGTG-3’
5’AGGCAAGCAGTGTAGAGAAAGA-3’
5’-CGATTTCCCAACCGCTTATGT-3’
5’-TTGTTACAAATCACCCCTCAAGG-3’
5’-CCCTGATACTTTTCTGGATGCC-3’
5’-CTTACCCGTCACAGCTTGCTA-3’
5’-CACTAAGAGATTGTTGCCATGCT-3’
5’-AAGAAGCGAAGACACCAACAG-3’
5’-TTTCGTAACGATCCATCCACTTT-3’
5’-AAAACGGGAGAGAGTCAGAATCA-3’
5’-ACGCTCACAAGACAAAAGGCA-3’
5’-TTGCCTGGGTTTTACCCTGC-3’
5’-AAGGCTTCCCACAGTTTCTGG-3’
5’-CTGAAGCCTATCAGGTGTTGTC-3’
5’-AGGGAGGTCCGTATATTCACAAT-3’
5’-TGTGGCTAATCCCTTGGTCAA-3’
5’-AGAACCAGTCATTGTGTGAGTTT-3’
5’-GGAACGAAAGTTACAGCACGA-3’
5’-CAAGCCCTGTCCTATCAAAAGT-3’
5’-CTAGTTCTCCACCCAAATGGATG-3’
5’-GCTGATAGGCTAGGTTCTGTAGG-3’
5’-CTGGACGACTTTACTGCCATC-3’
5’-TCCAACCGTGGGAATAATGCT-3’
5’-CCTGCACCGAAACCGAGTTAT-3’
5’-CCGTCATATTCGACTTTGGTTGC-3’
5’-ATTTACTCCTCCGGTGATAGGTT-3’
5’-GCATCTCCGATTTTGGTTGTACT-3’
5’-CTCTGGTGTTCTACGTGGTGA-3’
5’-GGAGCATGGTGACGGGAAT-3’
5’-ATGCTCGACTAATGGCCTATACA-3’
5’-CGTCGTGATCGTTCTTTATTGCT-3’
5’-CCGCCACACTCATCATAGCC-3’
5’-GGCCAAATAGGTTCCCAATCTG-3’
5’-TCCCAGTGTTCGGTGGATCT-3’
5’-TTGATGCGATGTGTGAAGACA-3’
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108 bp
118 bp
117 bp
60 bp
144 bp
139 bp
180 bp
117 bp
154 bp
103 bp
118 bp

114 bp
117 bp
105 bp
123 bp
196 bp
129 bp
131 bp

2.7 Plugs and Raft Culture
Plugs
First, we needed to determine how many plugs were required, and the mixture was
prepared for 2 more than the number of plugs to account for loss due to the viscosity of the
collagen. The plug mix consisted of 2.4 mL of rat tail collagen, at 4 mg/mL, 0.02M filtered
acetic acid, 0.3 mL of 10x filtered DME, and 0.3 mL of reconstitution buffer (RCB) for each
plug. 1M NaOH was also used to correct the pH.
J2 cells were harvested and pelleted so that there were approximately 1-2 x 106 cells per
plug. The 10x DME and RCB were added to the cell pellet, followed by the acetic acid. Finally,
the collagen was added and mixed by pipetting up and down. It was important that the mixture
remained cold to prevent the collagen from hardening. NaOH was added drop-wise until a redorange color was observed. Once the desired color was achieved, 3 mL of the mix was added to
each 3 cm dish, while limiting the number of bubbles. The plugs were incubated at 37°C for 30
minutes and were covered with 2 mL of E-media.
Rafts
After the plugs were made 1-2 x 106 cells of the various keratinocyte variants were
seeded onto each plug with 2 mL of E-media. The media was then refreshed every 24 hours until
it turned yellow. The plugs were then lifted out of the 3 cm dishes and placed onto metal grids in
10 cm3 dishes. The rafts were fed every 2 days with E-media, and it was crucial that the plugs
stayed dry and there were no bubbles coming into contact with the plugs. After approximately 13
days the rafts were flooded with 3.6% formaldehyde, diluted in DMEM, and they were taken to
histology for sectioning.
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2.8 Immunohistochemistry
Agitated Low Temperature Epitope Retrieval (ALTER)
A 1 L solution of 1x Ethylenediaminetetraacetic acid (EDTA) NaOH pH 8.0, 0.1%
Tween solution was prepared in deionized water and placed on a hotplate stirrer set to 65°C. The
slides that were received from histology were placed into a rack of Histoclear for 10 minutes.
After draining the Histoclear, the slides were transferred to IMS for 5 minutes and drained. The
slides were then washed 3 times in water and placed in H2O2 for 15 minutes. Another three
washes were performed in water, and the slides were then left overnight in the EDTA/Tween
buffer that was made.
The following day, the slides were removed from the buffer and equilibrated in PBSTween (0.1%) for 15 minutes. The slides were then individually wiped of excess PBS and were
sectioned by drawing with a wax pen. 50 µL of blocking buffer (10% HINGS, 1% BSA in PBS)
was carefully dropped onto each section and the slides were placed in a humidified chamber at
room temperature for 1 hour. Afterwards, the blocking buffer was removed and replaced with
antibody that was diluted in blocking buffer. The dilutions depended on the antibody that was
being used and ranged from 1/100 to 1/5000. The slides were placed back into the humidified
chamber and left in a cold room at 4°C overnight.
Three washes of PBS-Tween (0.1%) were performed with 15 minutes per wash. After the
third wash, the excess PBS was removed from the slides, and secondary antibody was added to
the sections. The secondary antibodies were diluted 1/500 in blocking buffer. The slides were
placed in the humidified chamber and left to incubate for 1-2 hours at room temperature. Three
more 15-minute washes of PBS-Tween (0.1%) were done, with the middle wash including 5 µL
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of 4′,6-diamidino-2-phenylindole (DAPI). Finally, the slides were mounted onto coverslips with
vectashield and stored at 4°C in the dark, until they were ready to view using the Zeiss
microscope.

3. Results
3.1 HeLa & SiHa Cells
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Figure 6. HeLa and SiHa qRT-PCR Data. Real-time quantitative PCR was performed on both the
HeLa cells (A) and SiHa cells (B) using DREAM and MMB gene primers. For both cell lines, four
variants were tested: WT, GFP, LIN52, and LIN52-S20C. Three repeats were performed for each variant,
and their average fold changes were plotted and used to generate standard error bars.

Based on the preliminary research, it was already observed that the LIN-52 S20C
mutation influences the proliferation and rate of growth in HeLa and SiHa cells. The expression
of various DREAM and MMB genes were also tested for in multiple variants of both HeLa and
SiHa cancer cell lines. When observing the SiHa sets (Figure 6B), the LIN52-S20C mutation
does not appear to play a significant role in the expression of these genes when compared to the
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other SiHa variants (GFP and LIN52). However, the HeLa cells (Figure 6A) are more promising
and do in fact show a clear downregulation of many of the genes that were tested for.

3.2 N/TERT-1 & HTK16 Keratinocytes
DREAM and MMB Gene Expression
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N/TERT-1 DREAM Primers
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Figure 7. N/TERT-1 DREAM and MMB qRT-PCR Data. The expression of DREAM (A) and MMB
(B) genes was tested for in N/TERT-1s, with and without the full HPV16 genome, using qRT-PCR.
N/TERT-1 + HPV16A and N/TERT-1 + HPV16B represent two clonal lines generated by infecting
N/TERT-1 cells with the full HPV16 genome. The average fold changes were taken for two repeats,
which were also used to generate standard error bars.

The N/TERT-1 cells were infected with the full HPV16 genome; from those cells that
were successfully infected, two clonal lines were developed: N/TERT-1 + HPV16A and
N/TERT-1 + HPV16B. We were then able test for any changes in gene expression in the
N/TERT-1 cells containing the full HPV16 genome compared to N/TERT-1 cells containing
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only GFP. By performing real-time quantitative PCR, we were in fact able to observe a
difference in expression in the cell lines containing the HPV genome. Not only was there an
increase in the expression of all the DREAM and MMB genes, but this increase was consistent in
both of the clonal cell lines that were tested.
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Figure 8. N/TERT-1 and HTK16 Growth Curves. Growth curves were generated for N/TERT-1 cells
(A), N/TERT-1 cells infected with the full HPV16 genome (B), and Htk16 cells (C). Depending on how
quickly the cells grew, they were seeded onto two dishes at 5 x 105 cells per dish every 2 to 4 days. The
cells were left to incubate until they were approximately 60-80% confluent, and they were counted and
seeded until four data points were collected and plotted.

Growth curves were generated for three different lines of keratinocytes. Each of the cell
lines contained three variants, and two of them were achieved through infections to express
either an excess of the wild-type LIN52 or the mutant LIN52-S20C. As expected, in the normal,
immortalized N/TERT-1 cell lines, the two variations had no effect on the overall rate of growth
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(Figure 8A). Since the cells did not contain the viral genome, there was no abnormal
proliferation that could have been counteracted by LIN52-S20C. In the N/TERT-1 cells
expressing the HPV16 genome, we observed that the expression of LIN52-S20C was sufficient
in slowing down the proliferation of the cells. Interestingly, we also observed that the increased
expression of WT LIN52 was also enough to slow their growth (Figure 8B). In the Htk16 cells
there was a clear distinction in the growth rate of the cells containing the LIN52-S20C variant.
Their rate was greatly decreased, while the WT LIN52 did not seem to have any noticeable
effects (Figure 8C).
Viral Life Cycle Analysis
BMYB
Figure 9. N/TERT-1 and N/TERT-1

D

A

+ HPV16 BMYB staining. N/TERT1 (A-C) and N/TERT-1 + HPV16 (DE

B

F) sections were stained using BMYB
(A, D) and DAPI (B, E). Images were
F

C

taken of the individual stains as well
as superimposed images (C, F).

When comparing the presence of BMYB in N/TERT-1 keratinocytes with and without
the full HPV16 genome, it is clear that the N/TERT-1 + HPV16 cells contain BMYB that is
distributed more evenly throughout the epithelium. The BMYB found in the uninfected
keratinocytes remains closer to the basal layer and becomes sparser as it reaches the outer
surface.
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LIN37
A

Figure 10. N/TERT-1 and N/TERT-

D

1 + HPV16 LIN37 staining.
N/TERT-1 (A-C) and N/TERT-1 +
B

E
HPV16 (D-F) sections were stained
using LIN37 (A, D) and DAPI (B, E).

C

F

Images were taken of the individual
stains as well as superimposed images
(C, F).

In both the N/TERT-1 keratinocytes with and without the HPV16 genome infection, there
does not seem to be any notable differences in the presence of LIN37.
LIN52-P
A

Figure 11. N/TERT-1 and N/TERT-

D

1 + HPV16 LIN52-P staining.
N/TERT-1 (A-C) and N/TERT-1 +
B

E
HPV16 (D-F) sections were stained
using LIN52-P (A, D) and DAPI (B,

C

F

E). Images were taken of the
individual stains as well as
superimposed images (C, F).

When stained for phosphorylated LIN52 (LIN52-P), we observed that the sections
containing the N/TERT-1 keratinocytes with HPV16 expressed much higher levels of LIN52-P
when compared to their uninfected counterparts. Although this was counter to what we expected,
it may be explained by the cell’s attempts to compensate for p130 loss.
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3.3 Mouse Embryonic Fibroblasts
Growth Curves and Cell Proliferation
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Figure 12. MEF WT LIN52 & LIN52-S20C Growth Curves, No Infection. MEFs bred to express
either the WT LIN52 or LIN52-S20C were obtained from the Litovchick lab at passage 2 (P2). They were
each seeded onto 2 dishes at 5 x 105 cells per dish and left to incubate until they were approximately 6080% confluent. Counts were collected until the 7th passage and plotted.

Before performing a growth curve analysis on the effects of HPV genes on the rate of
proliferation in the fibroblasts, it was first necessary to observe their growth rates in the absence
of any HPV genes. Once the MEFs were obtained, they were seeded on their 3rd passage and left
to grow. It was observed that the cells continued to proliferate until their 5th passage, and all
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consequent passages showed a decrease in cell counts. The cell counts were stopped after their
7th passage because the lower numbers made them difficult to count accurately.
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MEF LIN52-S20C Growth Curve
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Figure 13. MEF WT LIN52 & LIN52-S20C + HPV16 Genes Growth Curves. The MEF WT LIN52
(A) and MEF LIN52-S20C (B) cells were infected with various HPV16 genes. Each variant of the MEFs
was seeded onto 2 dishes to collect growth curve data. Multiple counts were collected for each variant
over a period of 32 days, apart from the LIN52-S20C variant, which did not survive long enough to
maintain accurate counts. The data was then plotted.

The mouse embryonic fibroblasts were infected with various HPV16 genes, including E2,
E6, E7, and both E6 & E7. Telomerase was used as a control. In all of the variants, except for the
E6 & E7 variant, the survival rates of the cells did not appear to have any drastic improvements.
At best, some of the variants maintained their cell numbers. However, in both the MEF WT
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LIN52 and the MEF LIN52-S20C cell lines, the E6/E7 variants had a substantial impact on the
rate of growth in the cells. The cells showed increased proliferation well beyond their 7th
passage.

MEF WT LIN52 & LIN52-S20C E6/E7 Growth Curves
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Figure 14. Comparing Growth Rates for MEF WT LIN52 + E6/E7 and MEF LIN52-S20C + E6/E7.
From the previous figures, we discovered that a combination of the HPV genes E6 and E7 resulting in an
increase in cell proliferation in both the WT LIN52 and LIN52-S20C MEFs. However, in order to better
understand how the rates of the mutant variants compared to the WT ones, we conducted another growth
curve experiment using only the WT LIN52 and LIN52-S20C cells that had been infected with E6 & E7.
Counts were collected over a 24-day period and plotted.
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Based on growth curves that were generated in Figure 10, we were able to conclude that
the HPV16 genes, E6 & E7, were sufficient to drive cell growth and proliferation. With that in
mind, another growth curve was generated, using only the E6/E7 infected MEFs but comparing
the rates of growth between the MEFs with WT LIN52 and the MEFs with the mutant LIN52S20C. The experiment showed that while E6 & E7 are able to promote proliferation in the MEF
LIN52-S20C cells, the rate was slower when compared to the MEF WT LIN52 cells.
DREAM and MMB Gene Expression
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Figure 15. Three variants were created for both the MEFs containing WT LIN52 and LIN52-S20C by
infecting the cells with the HPV16 E6, E7, or E6 and E7. Then qRT-PCR was performed using DREAM
(A) and MMB (B) primers. The values shown in the graphs represent the fold change of the MEF LIN52S20C variants relative to their corresponding MEF WT LIN52 variants.

In the HeLa cells, we observed that the expression of the LIN52-S20C mutation could
reduce the expression of many DREAM regulated genes. However, in our mouse embryonic
fibroblasts, we observed the opposite. In the MEFs containing the LIN52-S20C mutant, there
was an increased expression of DREAM (Figure 15A) and MMB (Figure 15B) genes when
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infected with E7 and E6/E7. On the other hand, the E6 mutation by itself did not appear to have
too great of an effect on the gene expression in the MEF LIN52-S20C cells.

4. Discussion
From past research and experimentation, the role of HPV and the rise of HPV-related
head and neck cell carcinoma has been well characterized. HNSCCs make up the sixth largest
category of cancers across all populations. While there are several causes for these cancer types,
studies have shown that high-risk HPVs, particularly HPV16, are the leading cause, accounting
for up to 70% of certain HNSCC types. The prevalence of HPV-associated HNSCCs has
consistently been on the rise, especially in male populations.
The HPV16 genome has been well-studied, especially its oncogenes, which include E7.
Among its many functions, its ability to target the family of pocket proteins has been attributed
to its transformative properties. Specifically, its interaction with the pocket protein, p130, has
come to light because of p130’s crucial role in the formation of the DREAM complex through
binding with LIN52. Preliminary research has shown that this interaction is necessary to re-enter
the cell cycle and promote cell proliferation and increased gene expression, making it a possible
therapeutic target for head and neck cell carcinoma. Specifically, we wanted to investigate the
effects of the HPV16 protein, E7, and DREAM complex genes as well as the ability of a specific
mutation, LIN52-S20C, to counteract those effects. In order to do so, we observed the gene
expression and growth of three major cell lines: cervical cancer cells, keratinocytes, and
fibroblasts.
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Although HPV-related cervical cancers are not identical to HPV-related HNSCCs, we
believed that findings from the cervical cancer cell lines could provide a strong foundation that
could be translated into head and neck cell lines. HeLa and SiHa cells were utilized for a number
of reasons. Not only were they immortalized, but they were fully transformed by high-risk HPVs
and developed from cervical cancer patients. Also, preliminary tests performed by Dr. Claire
James, a colleague at the Philips Institute for Oral Health Research, showed promising effects of
the LIN52-S20C mutation in both the HeLa and SiHa cells. She produced growth curves for both
cell lines and observed that in the HeLa and SiHa variants containing LIN52-S20C, there was a
noticeable decrease in their ability to proliferate. With this in mind, we performed qRT-PCR on
all the variants that were used in the growth curve production to see if there was any change in
the expression of DREAM and MMB target genes. Although there was no observable pattern in
the expression of genes in the SiHa cell lines, the results for the HeLa cells were more
promising. In 5 out of the 10 genes that were tested for, we were able to observe decreased gene
expression in the LIN52-S20C variants. It is important to note that, while HeLa and SiHa lines
are both derived from HPV-related cervical cancers, HeLa cells are HPV18 related and SiHa
cells are HPV16 related. This difference in HPV types may account for the differences observed
in our findings and could suggest that the LIN52-S20C mutation can be more successful in
HPV18-related cancers. However, our main focus was on HPV16 due to its high prevalence in
HNSCCs, but a focus on HPV18 can be a subject of focus in future works.
Keratinocytes were the second cell line that were used, and they included N/TERT-1 and
Htk16 lines. The N/TERT-1 keratinocytes share many characteristics with the oral keratinocytes
that one would expect to be infected in HNSCCs. N/TERT-1s were infected with the full HPV16
genome, using the lipofectamine transfection, and clonal cell lines were generated. Previously,
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Tara Nulton, another colleague at the Philips Institute, performed an RNASeq analysis on
N/TERT-1s with and without the HPV16 genome. She observed that 182 DREAM genes and 84
MMB genes were significantly upregulated in N/TERT-1s + HPV16. We performed an
expression analysis on N/TERT-1s with GFP and two HPV16 clonal cell lines, N/TERT-1 +
HPV16A and N/TERT-1 + HPV16B to see if we could corroborate the findings from the
RNASeq analysis. We were able to confirm those findings and observe an increase in all the
DREAM and MMB genes that were tested. This increase was also consistent across both of the
HPV16 infected lines. Raft cultures were also used to analyze the viral life cycle progression,
differentiation, and gene expression. These organotypic raft cultures provide a unique
environment that allows the keratinocytes to mimic their differentiation that is observed in
epithelium. By creating rafts containing both infected and uninfected N/TERT-1 keratinocytes,
we were able to observe any differences in their viral life cycles and their effects on the
differentiation of the epithelium. From the three sections that were used, the first noticeable
difference was that in the rafts containing the N/TERT-1 + HPV16 cells, there was an even
distribution of nuclei across the raft. On the other hand, the normal N/TERT-1 rafts presented
nuclei that were localized more basally. This suggests that when infected with HPV16, there is
less differentiation and more active cell cycle progression in the upper layers of the epithelium.
This is further supported by the observation that there is a greater presence of BMYB in the
upper layers of the N/TERT-1 + HPV16 epithelium. We know that the expression of BMYB and
its interaction with the MuvB core are essential to the progression of the cell cycle and the
activation of many transcription factors. Interestingly, we also observed a drastic increase in the
expression of phosphorylated LIN52 (LIN52-P) in the N/TERT-1 + HPV16s. Normally, LIN52
phosphorylation is necessary for the formation of the DREAM complex, so one would expect to
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see a greater expression of LIN52-P in quiescent cells; however, the opposite is seen here. This
can possibly be explained by the cells trying to overcompensate for a lack of p130. Since p130 is
degraded by E7, thereby disrupting the DREAM complex, there is less p130 available for
binding to LIN52. In an attempt to reestablish the DREAM complex, the cells can increase the
levels of LIN52-P that can bind to p130. It is also important to note that no notable changes were
observed in the LIN37 levels in the keratinocytes infected with HPV16. Finally, we wanted to
test whether or not we could affect the proliferation of HPV16 infected keratinocytes through the
LIN52-S20C mutation. In order to accomplish this, we first established a control growth curve
using uninfected N/TERT-1 keratinocytes with variants expressing normal protein levels, an
overexpression of WT LIN52, and the mutant LIN52-S20C. With this control, we wanted to
ensure that the LIN52-S20C mutation does not have any effects on the proliferation of N/TERT1 keratinocytes when the viral genome is not involved. Therefore, any differences observed in
HPV16 infected keratinocytes with LIN52-S20C can be attributed to the mutant’s interaction
with the viral genome. Once the control was established, we produced a growth curve for
N/TERT-1s containing the full HPV16 genome, using the same three variants. As expected, we
observed a decrease in the growth rate in the variants containing LIN52-S20C. Interestingly, we
also observed a similar decrease in the variants containing an overexpression of WT LIN52.
However, in the Htk16 cell lines, only the LIN52-S20C variants showed decreased proliferation.
While both the N/TERT-1 + HPV16s and the Htk16s both contain full HPV16 genome, only the
Htk16s were immortalized using the genome, while the N/TERT-1 + HPV16s were not. The
N/TERT-1 cells were immortalized prior to their infection with HPV16. As a result, the Htk16
cell lines are much more reliant on the viral genome. On the other hand, the N/TERT-1 cell lines
are less reliant on the genome for cell growth. That could be a possible explanation for why
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overexpression of WT LIN52 was sufficient for outcompeting HPV16 E7 and limiting
proliferation in N/TERT-1 + HPV16 cells.
In our final cell lines, the mouse embryonic fibroblasts were bred to express either WT
LIN52 or LIN52-S20C. The fibroblasts provide a solid foundation to observe the effects of
various HPV16 genes on the growth rate of cells because they have yet to be immortalized. This
means that after a certain number of passages, the fibroblasts will eventually cease to proliferate.
The growth curves that we produced for both the WT LIN52 and LIN52-S20C MEFs show that
they continue to proliferate until the 5th passage and begin to decrease in cell number. Both MEF
cell lines were then infected with various HPV16 genes, including E2, E6, E7, and E6/E7. When
growth curves were produced for all of the variants, we observed that the majority of the genes
did not have an impact on the growth of these cells. However, in the both the MEF WT LIN52
and MEF LIN52-S20C cell lines that were infected with E6 & E7, there was a considerable
increase in their growth rates. These findings are consistent with previous research that has
shown that a combination of E6 & E7 is sufficient for the immortalization and transformation of
cells.41,42 The growth in the MEFs containing E6/E7 are reminiscent of immortalized cells,
although their immortalization has not been confirmed. Ultimately, one of our main goals was to
investigate whether the LIN52-S20C mutation could reverse the adverse effects of the HPV16
genes. In order to do so, another growth curve was generated that compared only the E6/E7
variants of the MEF WT LIN52s and MEF LIN52-S20Cs. Although the infected MEF LIN52S20Cs also exhibited immortalized behavior and increased cell proliferation, there was a notable
decrease when compared to the WT LIN52 counterpart. Once all the growth curves were
generated, qRT-PCR was performed on the E6, E7, and E6/E7 variants to test for their gene
expression. The values for the MEF LIN52-S20Cs were then normalized to the values of the
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MEF WT LIN52s to see if the mutation had any effects on DREAM and MMB gene expression.
As expected, the MEFs infected with E6 did not appear to have much variation in their DREAM
and MMB expression. This is consistent with what we know about E6 and how it targets DNA
damage repair mechanisms and cell apoptosis, and unlike E7, its effects are less prominent in the
cell cycle and gene expression. However, although we expected to see a decreased expression in
the MEF LIN52-S20Cs, much like in the HeLa cells, the opposite was observed. Unfortunately,
the reasoning behind this inconsistency has yet to be resolved.
Ultimately, the goal was to gain a better understanding of the interactions between highrisk HPV16’s oncoprotein E7 and the cell cycle repressor, DREAM, in hopes of being able to
combat it using a mutated form of LIN52. We were able to observe the effects of HPV16 across
multiple cell lines in their increased gene expression and cell proliferation. Although we were
unable to completely negate these effects, we were able to see a lessening through the
incorporation of the LIN52-S20C mutant. In all three cell lines, we were able to observe that the
mutation could be used to slow the excessive cell growth that is characteristic of HPV-related
HNSCCs. Unfortunately, the gene expression analyses were not as conclusive, but they did
provide a foundation for future studies. As stated earlier, the findings in the HeLa qRT-PCR
suggests that the LIN52-S20C mutation may be more successful in combatting increased gene
expression linked to HPV18. Therefore, further studies into LIN52-S20C and the HPV18
genome may provide promising results. Also, the expression data for the MEFs yielded results
that were contradictory to what was expected. As a result, it would be helpful to perform an
RNASeq analysis to confirm that the data that was collected corresponds to the correct cell lines.
Finally, the hope is to expand our work in the MEFs into in vivo mice models to observe the
effects of the LIN52-S20C mutation in tumorigenesis and precancerous lesion formation.
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